Dow Jones

40,885.96

1.68%

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

CGEN

Compugen (CGEN)

Compugen Ltd

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CGEN

<< Anterior 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
14/03/2012	12:08	Edgar (US Regulatory)	Annual and Transition Report (foreign private issuer) (20-F)	NASDAQ:CGEN	Compugen Ltd
12/03/2012	05:15	Edgar (US Regulatory)	Statement of Ownership (SC 13G)	NASDAQ:CGEN	Compugen Ltd
27/02/2012	06:04	Business Wire	Compugen Presents Prediction Based Discovery Strategy at “Targets and Strategies for Drug Discovery” Conference	NASDAQ:CGEN	Compugen Ltd
14/02/2012	07:59	Edgar (US Regulatory)	Amended Statement of Ownership (SC 13G/A)	NASDAQ:CGEN	Compugen Ltd
07/02/2012	06:02	Edgar (US Regulatory)	Report of Foreign Issuer (6-K)	NASDAQ:CGEN	Compugen Ltd
07/02/2012	06:00	Business Wire	Compugen Ltd. Reports Fourth Quarter and Calendar 2011 Financial Results	NASDAQ:CGEN	Compugen Ltd
06/02/2012	06:00	Business Wire	Compugen to Present at the BIO CEO & Investor Conference 2012	NASDAQ:CGEN	Compugen Ltd
02/02/2012	05:00	Business Wire	Compugen Cancer Target Results Demonstrate Significant Potential for Cancer Immunotherapy	NASDAQ:CGEN	Compugen Ltd
31/01/2012	07:56	Business Wire	Compugen Fourth Quarter 2011 Conference Call Scheduled for Tuesday, February 7, 2012 at 10:00 AM EST	NASDAQ:CGEN	Compugen Ltd
30/01/2012	06:00	Business Wire	Compugen Presents Three Product Candidates for Treatment of Autoimmune Diseases at the Immunotherapeutics & Immunomonitoring ...	NASDAQ:CGEN	Compugen Ltd
20/12/2011	09:30	Business Wire	Compugen to Broaden and Accelerate Monoclonal Antibody Program for Oncology and Immunology	NASDAQ:CGEN	Compugen Ltd
13/12/2011	05:00	Business Wire	BioLineRx to Develop and Commercialize Novel Peptide Drug Candidates Discovered by Compugen	NASDAQ:CGEN	Compugen Ltd
30/11/2011	06:00	Business Wire	Compugen Presents Predictive Drug Target Discovery Platform at European Antibody Conference	NASDAQ:CGEN	Compugen Ltd
29/11/2011	06:00	Business Wire	Compugen and DiscoveRx® Form Collaboration to Commercialize Novel Peptide Ligands for GPCR Drug Targets	NASDAQ:CGEN	Compugen Ltd
08/11/2011	06:00	Business Wire	Compugen Reports Third Quarter 2011 Financial Results	NASDAQ:CGEN	Compugen Ltd
25/10/2011	06:00	Business Wire	Compugen's CGEN-15001 Pre-Clinical Data Presented at International Conference on Immune Tolerance	NASDAQ:CGEN	Compugen Ltd
24/10/2011	06:00	Business Wire	Compugen Third Quarter 2011 Conference Call Scheduled for Tuesday, November 8, 2011 at 10:00 AM EST	NASDAQ:CGEN	Compugen Ltd
12/10/2011	07:00	Business Wire	Pulmonary Fibrosis Foundation to Fund Further Therapeutic Evaluation Studies for Compugen-Discovered Drug Candidate	NASDAQ:CGEN	Compugen Ltd
13/09/2011	06:00	Business Wire	Compugen Announces Validation of Two Immune System Modulating Drug Candidates	NASDAQ:CGEN	Compugen Ltd
01/09/2011	15:06	Edgar (US Regulatory)	Prospectus filed pursuant to Rule 424(b)(5) (424B5)	NASDAQ:CGEN	Compugen Ltd
02/08/2011	06:00	Business Wire	Compugen Reports Second Quarter 2011 Financial Results	NASDAQ:CGEN	Compugen Ltd
27/07/2011	06:01	Business Wire	Compugen Second Quarter 2011 Conference Call Scheduled for Tuesday, August 2, 2011 at 10:00 AM EDT	NASDAQ:CGEN	Compugen Ltd
21/06/2011	07:06	Business Wire	Compugen Announces Initial Validation of Additional B7/CD28 Protein Family Based Product Candidate	NASDAQ:CGEN	Compugen Ltd
19/05/2011	06:00	Business Wire	Compugen Discloses Discovery Method for Drug Candidates That Interfere With Protein Conformations	NASDAQ:CGEN	Compugen Ltd
11/05/2011	06:45	Business Wire	Compugen Reports First Quarter 2011 Financial Results	NASDAQ:CGEN	Compugen Ltd
03/05/2011	08:00	Business Wire	Compugen First Quarter 2011 Webcast and Conference Call Scheduled for Wednesday, May 11, 2011 at 10:00 AM EDT	NASDAQ:CGEN	Compugen Ltd
27/04/2011	06:00	Business Wire	Compugen Discloses Splice Variant Based Program to Discover Superior Oncology Drug Targets for mAb Therapy	NASDAQ:CGEN	Compugen Ltd
07/03/2011	06:00	Business Wire	Compugen Announces Positive Animal Model Results for Novel Peptide Predicted to Block Protein-Protein Interaction	NASDAQ:CGEN	Compugen Ltd
15/02/2011	06:00	Business Wire	Compugen Ltd. Reports Fourth Quarter and Calendar 2010 Financial Results	NASDAQ:CGEN	Compugen Ltd
08/02/2011	06:00	Business Wire	Compugen Ltd. to Review Fourth Quarter and Year-End 2010 Financial Results on Tuesday, February 15, 2011	NASDAQ:CGEN	Compugen Ltd